M yocarditis is caused by various viruses. The therapeutic potential of several drugs has been investigated in experimental murine myocarditis.1-8 Traditionally, congestive heart failure in patients has been considered to be a contraindication for the use of P-adrenergic receptor blockers. However, recent studies have suggested that these agents can have beneficial effects9-15 and can improve survival16 in patients with dilated cardiomyopathy. Although myocarditis is thought to be one of the causes of dilated cardiomyopathy,1718 few studies have investigated the role of ,B-adrenergic blockers in viral myocarditis. 19 A few reports are available on the effects of ,3-adrenergic blockers with intrinsic sympathomimetic activity in dilated cardiomyopathy,20,21 and these reports do not indicate any beneficial effect of short-term regimens. However, long-term regimens with bucindolol have improved cardiac function. 15 We have already reported an animal model of myocarditis induced by the encephalomyocarditis virus, which shows congestive heart failure in the acute stage22 and lesions similar to those caused by dilated cardiomyopathy in the chronic stage. 23 In this study, we investigated the effects of carteolol on our animal model and compared them with the effects of metoprolol.
Methods

Experimental Infection and Treatment
Four-week-old inbred male BALB/c or DBA/2 mice were inoculated intraperitoneally with 0.1 ml of the M variant of encephalomyocarditis virus diluted in Eagle's minimal essential medium to a concentration of 100 plaque-forming units (pfu)/ml.
Acute experiment. To investigate the effect of carteolol on virus replication, BALB/c mice were given carteolol at a dose of 1 (n=10), 10 (n=10), 30 (n=11), or 100 mg/kg (n=9), or distilled water (n=23). Treatment was performed by daily subcutaneous injection starting on the day of inoculation. Mice were killed on day 7. The heart was used for plaque assay of the virus content. To investigate the effect of carteolol on survival and histopathological change, DBA/2 mice were given carteolol at a dose of 1 (n=9) or 10 mg/kg (n=9), or distilled water (n=8) orally daily for 14 days beginning on the day of inoculation and were then killed. After weighing the hearts, they were sectioned and histopathologically examined.
Subacute experiment. DBA/2 mice were inoculated with the virus and were given carteolol at a dose of 1 (n=12) or 10 mg/kg (n=16), or distilled water (n =27) subcutaneously daily starting on day 14 after inoculation. Mice were killed on day 28. After weighing the hearts, they were sectioned and histopathologically examined.
Chronic experiment. DBA/2 mice were inoculated and were given carteolol at a dose of 1 (n = 13) or 10 mg/kg (n=9), metoprolol at 30 mg/kg (n=9), or distilled water (n=31) orally daily starting on day 14 after inoculation. Mice were killed on day 104. After weighing the hearts, they were sectioned transversely and histopathologically examined.
Myocardial Virus Titrations
Myocardial virus titrations were performed with a plaque assay method as previously described.' Myocardial virus titers were expressed as log1o pfu/mg heart.
Histopathological Examination
Hearts were fixed in 10% formalin and sectioned along the long axis through the atria and ventricles in the acute and subacute experiments. In the chronic experiment, hearts were sectioned transversely (perpendicular to the long axis) at the maximal circumference of the ventricle after fixation in 10% formalin. The heart tissues were embedded in paraffin and stained with hematoxylin-eosin. The wall thickness and the cavity dimension of the left ventricle were measured to the nearest 0.01 mm with an ocular micrometer. Myocardial fiber diameter of the left ventricle was determined by measuring the shortest diameter at the level of the nucleus of 40 myocardial fibers in the stained cross-sections with an ocular micrometer. Myocardial cell necrosis, fibrosis, cellular infiltration, and calcification were graded by two observers, who were not aware of treatment regimens, and were scored as follows: 0, no lesions; 1+, lesions involving less than 25% of the myocardium; 2+, lesions involving 25-50% of the myocardium; 3+, lesions involving 50-75% of the myocardium; and 4+, lesions involving 75-100% of the myocardium. The scores obtained from two observers were averaged.
Statistical Analysis
Survival was analyzed by the Kaplan-Meier method. Statistical analysis of the data for body weight, heart weight, heart weight to body weight ratio, myocardial virus titers, histological score, left ventricular wall thickness, left ventricular cavity dimension, and myocardial fiber diameter of the left ventricle was performed by one-way analysis of variance (ANOVA). Values are given as mean+SD.
Results
Acute Experiment
Myocardial virus titers on day 7 were similar among the groups: 2.1±0.9 log10 pfu/mg heart in the infected control group, 1.9+±0.9 log10 pfu/mg heart in mice given carteolol at 1 mg/kg day, 2.5+± 1.0 log10 pfu/mg heart at 10 mg/kg/day, 2.4±1.1 log10 pfu/mg heart at 30 mg/kg/day, and 2.1±0.8 log10 pfu/mg heart at 100 mg/kg/day. Viral replication in the heart was not influenced by carteolol. There were no significant differences between groups in regard to survival, heart weight to body weight ratio, and histopathological findings on day 14 (Table) .
Subacute Experiment
Before the assignment of treatment of mice on day 14, 45.9% (40 of 87) of the mice had died. Survival rates after starting carteolol treatment were not significantly different among these groups. Body weight, heart weight, and the heart weight to body weight ratio were similar in each group. The histopathological findings were not significantly different among the groups (Table 1) .
Chronic Experiment
Survival rate. Before the assignment of treatment of mice on day 14, 58.9% (89 of 151) of the mice had died. The survival of the infected control group after day 14 was 64.5% (20 of 31). The survival was 76.9% (10 of 13) in mice given carteolol at 1 mg/kg/day, 66.7% (six of nine) at 10 mg/kg/day, and 77.8% (seven of nine) in mice given metoprolol. There were no significant differences between the groups.
Body Weight, Heart Weight, and Heart Weight to Body Weight Ratio Although body weight was similar in each group, heart weight was significantly lower in mice given carteolol at 1 (124±19 mg, p<0.01) or 10 mg/kg/day (114±19 mg,p<0.01) than that in the infected control group (167±23 mg) (Figure 1) . Therefore, the heart weight to body weight ratio in mice given carteolol at 1 (5.3+0.4x 10-3, p<0.01) and 10 mg/kg/day (5.1±0.7x10-3, p<0.01) was significantly lower than that in the infected control group (7.1 ± 1.0x 10-3). Metoprolol did not cause a significant change in heart weight or the heart weight to body weight ratio.
Histopathological Examination
In the chronic stage, cellular infiltration was not found, and the extent of fibrosis and calcification was increased. The histological scores of myocardial fibrosis were 2.1±0.9 in the infected control group, 1.4±0.5 in mice given carteolol at 1 mg/kg/day, 1.2+0.8 at 10 mg/kg/day, and 2.1±1.1 in mice given metoprolol. Scores of calcification showed the same pattern as the fibrosis scores. Histological scores for mice given carteolol at 10 mg/kg/day were significantly lower (p<0.05) than those for the infected control group and the metoprolol-treated group (Figure 2 ). Representative histological sections are shown in Figures 3A-3C . On day 104, hearts of mice without carteolol treatment showed dilatation and hypertrophy ( Figure 3D ). However, carteolol pre- (n-7) (n-10) (n-6) * P<0.05 **P<0.01 FIGURE 1. Bar graphs of effects of carteolol and metoprolol on body weight, heart weight, and heart weight to body weight ratio in the chronic experiment. Heart weight and heart weight to body weight ratio of mice given carteolol at 1 and 10 mg/kg/day were significantly lower than those of the infected control group. Heart weight of mice given carteolol at 10 mg/kg/day and heart weight to body weight ratio of mice given carteolol at 1 and 10 mg/kg/day were also significantly lower than those of mice given metoprolol. On the other hand, heart weight and heart weight to body weight ratio of mice given metoprolol were similar to those of the infected control group.
vented those findings ( Figure 3E ). Metoprolol did not cause any change of those findings ( Figure 3F 
gum).
However, the fiber diameter in mice given metoprolol was similar to that in the infected control group.
Discussion
Carteolol is a nonselective f8-adrenergic blocker with moderate intrinsic sympathomimetic activity and little membrane stabilizing activity.24-27 It has about a 20-30-fold stronger ,B-adrenergic blocking effect per unit weight than propranolol. Although the elimination half-life of carteolol is relatively short at 3-7 hours, the pharmacological half-life is long (approximately 17 hours),25'26 so a sufficient /3-adrenergic blocking effect can be obtained with a single daily dose.
To our knowledge, there has been only one published report19 on the effects of ,B-adrenergic blockers on myocarditis. In that study, the effect of metoprolol on acute coxsackievirus B3 in a murine model of myocarditis was examined. There was an increase in the mortality of the mice and in severe pathological changes of the hearts of mice given metoprolol at 32.5 mg/kg/day. The deleterious hemodynamic and immunologic effects of metoprolol were considered to cause these findings because the myocardial virus titer was increased. On the other hand, in our experiment, moderate doses of carteolol had no deleterious effect on survival, heart weight to body weight ratio, histopathological findings, or myocardial virus titer in the acute and subacute stages. Thus, carteolol did not worsen viral myocarditis in these mice. The difference may be due to differences in the strain of mice, the virus, or the /3-adrenergic blocker. 30 A variety of mechanisms of the effect of f3-adrenergic blockers have been suggested, including 1) decreased myocardial energy demand, 2) improved diastolic relaxation, filling, and compliance, 3) protection of myocytes against the direct toxic effects of catecholamines, 4) inhibition of sympathetically mediated vasoconstriction through the release of prostaglandins and renin, 5) upregulation of 83-adrenergic receptors,33,34 and 6) anti-ischemic and antiarrhythmic effects. Another recently suggested mechanism is that the immune function is regulated in part by the sympathetic nervous system.3536 In view of the evidence for impaired cellular and humoral immunity in dilated cardiomyopathy such as defective natural killer and suppressor cell activities3738 and of the existence of autoantibodies against the cardiac /3-adrenergic receptors,39 it is certainly possible that inhibiting the effect of catecholamines on the immune system by ,B-adrenergic blockers may lead to reversal of some of these immune abnormalities. However, the detailed mechanism of action of 83-adrenergic blockers is unknown, and several mechanisms are believed to interact cooperatively. One of the reasons why the mechanism of their action has been difficult to define is that few reliable animal models of dilated cardiomyopathy are available. Although some investigators believe that the cardiomyopathic Syrian hamster is a model of human dilated cardiomyopathy,40-42 congestive heart failure generally does not occur until after 250 days, and the occurrence of the disease is not uniform. Therefore, to examine whether drug therapy can effectively prevent cardiomyopathy in these hamsters is difficult. There are a few reports that propranolol therapy is partially protective in this model.4344 However, many other investigators believe that the Syrian hamster is not a good model of dilated cardiomyopathy. 
